Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging

详细信息    查看全文

• 作者：Tobias Baumann ; PD ; Dr Med^a (Consultant in Radiology) ; Christof Rottenburger ; Dr Med^a ; ^b (Consultant in Nuclear Medicine) ; Guillaume Nicolas ; Dr Med^a ; ^c (Consultant in Nuclear Medicine) ; Damian Wild ; Prof Dr Med et Phil^a ; ^b ; ^{damian.wild@usb.ch" class="auth_mail" title="E-mail the corresponding author} (Consultant in Nuclear Medicine)
• 关键词：GEP NET ; gastroenteropancreatic neuroendocrine tumour ; somatostatin receptor imaging ; SRS ; glucagon-like peptide-1 receptor imaging ; PET/CT
• 刊名：Best Practice Research Clinical Endocrinology Metabolism
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：30
• 期：1
• 页码：45-57
• 全文大小：827 K

文摘

Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainly on morphological imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). Molecular imaging techniques also in combination with CT (hybrid imaging) greatly benefit patient management, including better localization of occult tumours and better staging. Somatostatin receptor scintigraphy (SRS) and somatostatin receptor (SSTR) positron emission tomography (PET) play a central role in the diagnostic work-up of patients with well-differentiated GEP-NETs. SSTR PET/CT is superior to SRS and should be used whenever available. ¹⁸F-DOPA and ¹⁸F-FDG PET/CT is inferior to SSTR PET/CT at least in patients with well-differentiated GEP-NETs. Both SSTR PET/CT and SRS have limitations, such as relatively low detection rate of benign insulinomas, poorly differentiated GEP-NETs and liver metastases. New innovations such as SSTR PET/MRI, radiolabelled SSTR antagonists and glucagon-like peptide-1 receptor (GLP-1R) agonists might further improve imaging of GEP-NETs.